Bristol-Myers Squibb 2026 Key Milestones Set to Impact Guidance

Key 2026 clinical milestones Bristol-Myers Squibb (BMS) is targeting that could influence guidance

Based on BMS’s 2026 outlook commentary in its Q1 2026 earnings transcript, the company is effectively highlighting two kinds of milestones that matter for guidance: (1) late-stage readouts near year-end (potentially driving regulatory and commercial expectations), and (2) multiple mid-to-late development updates expected by end of 2026 (supporting probability-weighted forward planning and near-term confidence). Below are the specific milestones referenced.

---

1) Late-2026 pivotal/major readouts BMS expects to “define and derisk” its long-term growth

BMS explicitly characterizes the latter part of 2026 as “shaping up” to include an “increasing cadence of pivotal readouts” expected to further define and derisk its long-term growth profile. ¹

A. Milvexian (Factor XI inhibitor) in atrial fibrillation (AFib) and secondary stroke prevention (SSP)

• BMS expects AFib and SSP outcomes to be “expected by the end of the year”. ²
• It also states trials are event-driven and BMS remains blinded, with the DMC oversight recommending continuation “as planned” in a recent meeting. ²
• BMS describes the end-of-year AFib trial as testing non-inferiority vs. apixaban, followed by superiority testing for bleedings. ³

Why this could influence guidance: AFib/SSP catalysts are large-market opportunities; BMS frames these as central to its “lead” position in thrombotic space as a Factor XI inhibitor company. ² Positive efficacy/bleeding outcomes could increase confidence in future revenues and reduce perceived risk for a major growth driver; conversely, weaker outcomes could require adjustments to outlook assumptions.

---

B. Cobenfy (Alzheimer’s psychosis) — clinical readout timing and implications

• BMS identifies “Cobenfy Alzheimer’s psychosis” as one of the Phase III readouts expected late in 2026. ¹
• Elsewhere in the transcript, BMS ties its confidence to existing program design/execution and references prior data and study designs in the broader Cobenfy development path. ⁴
• BMS further frames Cobenfy’s program as a multi-“shot on goal” approach (multiple studies across psychosis-related indications). ⁵

Why this could influence guidance: a late-2026 Phase III readout for Alzheimer’s psychosis would be a potential swing factor for near- and medium-term growth expectations, particularly because BMS highlights multiple Cobenfy-related contributions to growth portfolio performance and ongoing launch progress. ⁶⁷

---

C. Iberdomide (CELMoD) — NIM “PFS data” expected late 2026

• BMS states “Iberdomide… in NIM” and that it is expecting the PFS later this year. ²
• It also references that this filing has a PDUFA date of August (shown earlier in the transcript with the specific date August 17), and that the FDA granted breakthrough therapy designation and priority review. ⁶

Why this could influence guidance: progression-free survival (PFS) data is a key efficacy milestone that can materially affect perceived probability of regulatory success and the commercial trajectory of CELMoD franchise opportunities. ²⁶

---

D. Admilparant (immune/inflammation) — IPF and PPF milestones relative to year-end

BMS highlights “Admilparant in immunology, in IPF and PPF” as a critical readout. ⁴

• BMS says IPPF/“IPF” is guided by the end of the year, while “PPF will be just a few months later, probably beginning ’27.” ⁴

Why this could influence guidance: this positioning implies a near-term evidence update for two difficult-to-treat indications, potentially affecting growth modeling for its “novel mechanism,” including both efficacy and safety profile expectations. ⁴

---

2) Additional 2026 clinical milestone events explicitly expected by end of year (supporting confidence)

Although BMS’s most guidance-impacting framing is the “late-2026” pivotal cadence, it also provides other end-of-year expectations:

A. NSCLC/Neuroscience CELMoDs (ADP studies) — multiple readouts by end of 2026

• BMS says that in neuroscience, it continues to expect “ADP studies, a den, 2 and 4” readouts “by the end of the year.” ²
• It adds that it “needs the 2 studies probably for an approval.” ²

Why this could influence guidance: even if approval is tied more directly to specific studies, end-of-year readouts can influence the company’s confidence, probability-weighted pipeline value, and timing expectations for potential regulatory filings or further development steps. ²

---

3) How these milestones connect to BMS’s stated guidance stance

BMS explicitly states it is reaffirming full-year 2026 financial guidance and that performance is tracking toward the upper end of revenue/EPS guidance based on Q1 results and current projections. ⁸

Interpretation (grounded in the transcript framing): the clinical milestones above are not presented as reasons to change guidance in Q1; instead, they are presented as catalysts that will increase data richness into 2026/2027 and “define and derisk” the long-term growth profile, which can later translate into guidance updates as the year progresses. ²¹⁸

---

Summary table of 2026 clinical milestones highlighted in the transcript

---

Bottom line: In 2026, BMS is emphasizing year-end pivotal catalysts primarily around Milvexian (AFib/SSP), Cobenfy (Alzheimer’s psychosis), Iberdomide (NIM PFS), and Admilparant (IPF/PPF), plus additional neuroscience ADP readouts by year-end. ⁴²¹ These milestones are positioned as key events that can affect future expectations, even while BMS is currently reaffirming full-year 2026 guidance. ⁸